1. Home
  2. CISO vs MBRX Comparison

CISO vs MBRX Comparison

Compare CISO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CISO Global Inc.

CISO

CISO Global Inc.

HOLD

Current Price

$0.27

Market Cap

13.2M

Sector

Technology

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$3.27

Market Cap

13.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISO
MBRX
Founded
2015
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
13.1M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
CISO
MBRX
Price
$0.27
$3.27
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
497.2K
327.0K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
79.31
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.26
52 Week High
$1.48
$7.98

Technical Indicators

Market Signals
Indicator
CISO
MBRX
Relative Strength Index (RSI) 41.20 69.78
Support Level $0.25 $3.13
Resistance Level $0.32 $5.22
Average True Range (ATR) 0.04 0.23
MACD -0.01 0.06
Stochastic Oscillator 33.73 87.60

Price Performance

Historical Comparison
CISO
MBRX

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity compliance and is a software firm composed of trained and seasoned security professionals. The services are used to protect clients' data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in the U.S., Chile, and all other countries. The maximum revenue is generated from the U.S. The products and services include: security managed services, professional services, and cybersecurity software.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: